🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruitingn/aAges 18 Years - anyAllIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT06720870 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study is a pilot, observational, retrospective, and (italian) multicenter study. The study will involve the collection of patient data from medical records for patients with Multicentric Castelman Disease Relapsed/Refractory who received treatment with at least one dose of siltuximab, as part of standard of care in a real-life context, from July 2016 till April 2022 in 31selected italian centres.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Histologically confirmed diagnosis of R/R MCD HIV and HHV-8 negative patients who underwent siltuximab in a real-life context from July 2016 till April 2022. 2. Age ≥ 18 yearsatenrollment 3. Signature of written informed consent (where applicable) Exclusion Criteria: 1\. R/R MCD patients who underwent siltuximab in a clinical trial context
💊

What it tests

  • Not listed
📍

Where

12 sites
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Italy
Azienda Ospedaliera Sant'Anna e San Sebastiano
Caserta, Italy
Policlinico di Bari - Azienda Ospedaliero Universitaria Consorziale Policlinico
Bari, Italy
Azienda Ospedaliera Universitaria Arcispedale Sant'Anna
Ferrara, Italy
Azienda Ospedaliero Universitaria Careggi
Florence, Italy
Irccs Ospedale San Raffaele
Milan, Italy
Azienda Ospedaliero-Universitaria "Maggiore della Carità"
Novara, Italy
Azienda Ospedaliera Di Padova
Padova, Italy

…and 4 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy